Liliane J Striker

US Patent:

20010005720, Jun 28, 2001

Filed:

Apr 16, 1997

Appl. No.:

08/840777

Inventors:

GARY E. STRIKER - MIAMI FL, US
LILIANE J. STRIKER - MIAMI FL, US

Assignee:

U.S.A. AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

International Classification:

A61K031/715
A01N043/04

US Classification:

514/054000

Abstract:

A method of treating a mammalian patient suffering from a chronic progressive vascular scarring disease (CPVSD), particularly arteriosclerotic diseases such as atherosclerosis, to halt or at least slow substantially the progress of the disease and cause resolution and/or diminution of already-formed scarring and lesions. The method consists of the administration to the patient of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred, with the total daily dosage of PPS or PPS salt ranging from about 5 to about 30 mg/kg of patient body weight, or about 350 to about 2,000 mg per day in adult human patients.

US Patent:

56438923, Jul 1, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/478347

Inventors:

Gary E. Striker - Bethesda MD
Liliane J. Striker - Bethesda MD
Fred P. Sherman - Hollywood FL

Assignee:

Baker Norton Pharmaceuticals, Inc. - Miami FL
The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3170

US Classification:

514 54

Abstract:

A method of treating a mammalian patient suffering from a chronic progressive vascular disease (CPVD) characterized by scarring and/or fibrosis to halt the progress of the disease and cause resolution of already-formed scarring or fibrotic lesions. The method consists of the administration to the patient of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred, with total daily dosage of PPS or PPS salt ranging from about 50 to 1200 mg per day.

US Patent:

6187745, Feb 13, 2001

Filed:

Oct 1, 1998

Appl. No.:

9/168974

Inventors:

Gary E. Striker - Miami FL
Liliane J. Striker - Miami FL
Kenneth H. Kortright - Pembroke Pines FL

Assignee:

Baker Norton Pharmaceuticals, Inc. - Miami FL
The United States of America as represented by the Department of Health and
Human Services - Washington DC

International Classification:

A61K 3800

US Classification:

514 11

Abstract:

A method of preventing, reducing or reversing nephrotoxicity or renal dysfunction induced by administration of a cyclosporin or tacrolimus to a mammalian patient. The method comprises the co-administration to the patient, either before, together with or after cyclosporin or tacrolimus administration, of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred. The total daily dosage of PPS or PPS salt ranges from about 2 to about 50 mg/kg of patient body weight, or about 140 to about 3,500 mg per day in adult human patients. Also disclosed are a method of providing immunosuppressive therapy to a patient while avoiding cyclosporin or tacrolimus-induced nephrotoxicity, and combination pharmaceutical compositions to be used in such therapy.

US Patent:

62145428, Apr 10, 2001

Filed:

Oct 20, 1992

Appl. No.:

7/963475

Inventors:

Gary E. Striker - Bethesda MD
Liliane J. Striker - Bethesda MD
Emmanuel Peten - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and
Human Services - Washington DC

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

The state of the extracellular matrix of discrete tissue subsegments can be determined via an approach that combines microdissection, reverse transcription and polymerase chain reaction. Using this approach, a positive correlation between a fibrotic condition and alterations in messenger RNA levels of matrix components provides the basis for (i) the diagnosis of a fibrotic disease and (ii) the monitoring of the efficacy of a therapeutic regimen.